Last reviewed · How we verify
NCT06008288
A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.
Phase 2 trial testing JAB-21822 in KRAS P.G12C in 88 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | Allist Pharmaceuticals, Inc. |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 88 |
| Start date | 27 October 2023 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2027 |
| Sites | 31 locations across China |
Drugs / interventions tested
- JAB-21822 — full drug profile →
Conditions studied
- KRAS P.G12C — all drugs for KRAS P.G12C →
- Pancreatic Cancer — all drugs for Pancreatic Cancer →
- Solid Tumor — all drugs for Solid Tumor →
Sponsor
Allist Pharmaceuticals, Inc. — full company profile →
Who can join
18 and older, any sex, with KRAS P.G12C or Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients with other advanced solid tumors (excluding NSCLC and CRC) who have progressed after prior systemic therapy or are intolerant and lack satisfactory alternative treatment options, aiming to evaluate the efficacy and safety of Glecirasib in these patients.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer.
Casacuberta-Serra S, González-Larreategui Í, Capitán-Leo D, Soucek L. · · 2024 · cited 43× · PMID 39164274 · DOI 10.1038/s41392-024-01907-z -
Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies.
Linehan A, O'Reilly M, McDermott R, O'Kane GM. · · 2024 · cited 24× · PMID 38576709 · DOI 10.3389/fmed.2024.1369136 -
Inhibition of the RAF/MEK/ERK Signaling Cascade in Pancreatic Cancer: Recent Advances and Future Perspectives.
Adamopoulos C, Cave DD, Papavassiliou AG, Papavassiliou AG. · · 2024 · cited 19× · PMID 38338909 · DOI 10.3390/ijms25031631 -
Targeting RAF dimers in RAS mutant tumors: From biology to clinic.
Yin H, Tang Q, Xia H, Bi F. · · 2024 · cited 9× · PMID 38799634 · DOI 10.1016/j.apsb.2024.02.018 -
Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials.
Li J, Deng T, Gu Y, Calles Blanco A, et al · · 2025 · cited 6× · PMID 41037823 · DOI 10.1002/cac2.70056 -
Unveiling the Promise: Navigating Clinical Trials 1978-2024 for PDAC.
Dominguez AA, Perz MT, Xu Y, Cedillo LG, et al · · 2024 · cited 5× · PMID 39518005 · DOI 10.3390/cancers16213564 -
Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312.
Wang P, Sun X, He X, Kang D, et al · · 2025 · cited 4× · PMID 40304209 · DOI 10.1158/2767-9764.crc-25-0001 -
Drugging the 'undruggable' KRAS: breakthroughs, challenges, and opportunities in pancreatic cancer.
Khan N, Raza U, Ali Zaidi SA, Nuer M, et al · · 2025 · cited 3× · PMID 40624835 · DOI 10.20892/j.issn.2095-3941.2025.0122
Verify or expand the search:
- PubMed search for NCT06008288
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of JAB-21822
Trials testing the same drug.
- NCT06416410 — JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer Wit · Phase 3 · recruiting
- NCT06162169 — A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects · Phase 1 · completed
- NCT05875493 — A Food Effect Study of JAB-21822 in Healthy Subjects · Phase 1 · completed
Other recruiting trials for KRAS P.G12C
Currently open trials in the same condition.
- NCT05631249 — Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C · Phase 2 · recruiting
- NCT05398094 — Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy · Phase 2 · recruiting
Other Allist Pharmaceuticals, Inc. trials
Trials by the same sponsor.
- NCT07010419 — A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With St · Phase 3 · recruiting
- NCT06416410 — JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer Wit · Phase 3 · recruiting
- NCT06162169 — A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects · Phase 1 · completed
- NCT05920941 — Mass Balance Study of [14C]JAB-21822 · Phase 1 · completed
- NCT05875493 — A Food Effect Study of JAB-21822 in Healthy Subjects · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06008288 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Allist Pharmaceuticals, Inc.
- Last refreshed: 13 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06008288.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing